Med Universe AB (“MedUniverse”) announced today, September 4th 2019, that the company has been awarded the European Commission grant under the SME programme Horizon 2020, with significant appraisal score of “Very good to Excellent”.
Horizon 2020 EU funding supports Small and Medium-sized Enterprises (SME) with breakthrough innovation technology and high potential of market creation and expansion within EU and beyond. The highly competitive fund is offered to SMEs which fall under European Innovation Council’s (EIC) SME definition. The fund offers Europe’s brightest and boldest entrepreneurs the funding for breakthrough ideas with the potential to create entirely new markets and/or to revolutionize existing ones. The round of applications in May 2019, has been highly competitive.
MedUniverse is honored to announce that the company has been awarded the phase I grant for its patient case engagement platform with adjacent consulting services to drive increased HCP engagement and better results via the power of patient cases. MedUniverse received a significant total score of 13.80 out of 15, which indicates “Very good to Excellent” in the appraisal scale. The company’s application received excellent scores for major sub-criterions, such as (but not limited to):
- Impact: convincing description of target audience and needs, willingness to pay for the innovation, uniqueness of innovation, clear identification of market opportunity and creation, realistic and relevant description of scale up.
- Excellence: highly innovative solution that goes beyond the state of the art compared to existing solutions.
- Quality and efficiency of implementation: relevant technical/business experience of a committed management team, realistic and comprehensive timeframe.
The SME instrument will boost faster growth and market creation for MedUniverse. Following the completion of phase I, MedUniverse is preparing to apply for phase II of the Horizon 2020 grant, to be submitted in Q1 2020.
Comments from MedUniverse’s CEO, Anna Omstedt
” We are proud to receive this €50,000 grant from the European Commission! It is a clear sign of recognition that our innovation is helping society reduce medication errors, optimize precision medicine and ultimately improve patient outcomes.
The Seal of Excellence Rating proves that we are on the right track and motivates us to prepare the feasibility report, as the phase I requirement by European Commission, which will then be the basis for the upcoming phase II application.
For more information, please contact:
Anna Omstedt – CEO, Med Universe AB
Phone: +46 70 772 63 64
E-mail: anna.omstedt@meduniverse.com
www.meduniverse.com
